1 asset in Parotid Gland Cancer
Therapeutic assets addressing Parotid Gland Cancer, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Pembrolizumab Parotid Gland Cancer | Merck Sharp & Dohme LLC | P2 | CCC (53) |
Therapeutic assets addressing Parotid Gland Cancer, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Pembrolizumab Parotid Gland Cancer | Merck Sharp & Dohme LLC | P2 | CCC (53) |